Combination of docetaxel and capecitabine in the neoadjuvant chemotherapy of breast cancer
- VernacularTitle:多西他赛联合卡培他滨在乳腺癌新辅助化疗中的应用
- Author:
Weifeng SHI
;
Shifu ZHOU
- Publication Type:Journal Article
- Keywords:
breast cancer;
neoadjuvant chemotherapy;
docetaxel;
capecitabine
- From:
China Oncology
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Neoadjuvant chemotherapy has become a major therapeutic strategy for the treatment of locally advanced breast cancer.Randomized trials comparing this approach to adjuvant chemotherapy have demonstrated that neoadjuvant chemotherapy was as efficacious as adjuvant chemotherapy and allowed for a higher rate of breast conservation.This study was to evaluate the efficacy and toxicity of docetaxel plus capecitabine in the neoadjuvant chemotherapy of locally advanced breast cancer(LABC) .Methods:Fifty-two patients with LABC were treated with docetaxel 75 mg/m2,d1;Capecitabine 2 000 mg/m2,d1-14.The chemotherapy was repeated every 3 weeks.Effi cacy and toxicities were reviewed after 3 to 4 cycles of chemotherapy.Results:The CR+PR rate was 80.7%.A pathological complete response in the breast was achieved in 5.8% of patients after 4 cycles of docetaxel/capecitabine.The adverse reactions were neutropenia,alopecia and hand-foot syndrome.Conclusion:The combination of docetaxel and capecitabine was well tolerated and effective in LABC for neoadjuvant chemotherapy.
